Pharma, R&D

Shifting focus, Sanofi agrees to pay Regeneron $462M for an early wrap of their big I/O alliance

Sanofi has agreed to hand $462 million to Regeneron for an early wrap to their immuno-oncology alliance, narrowly limiting an R&D relationship that will now concentrate on 2 lead programs in the clinic and leaving each of the companies free to pursue their own fates in I/O as they move to begin shuttering one of the industry’s most productive development alliances.


In order to read this article, you must be an Endpoints News subscriber. (It's free to subscribe.)

← Go back

We produce two daily email newsletters designed to give you a complete picture of what's important in biopharma. It's free to subscribe and never any spam. Join 51,200+ biopharma executives who read Endpoints News every day.

Access is subject to the terms in our Privacy Policy.


The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 51,200+ biopharma pros who read Endpoints News by email every day.

Free Subscription

VP Oncology Biology
Skyhawk Therapeutics Waltham, MA
Associate Director CMC
Elektroki Boston, MA
Director Process Development
Elektroki Boston, MA
Research Scientist - Immunology
Recursion Pharmaceuticals Salt Lake City, UT

Visit Endpoints Careers ->